Synmosa Biopharma (4114) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Synmosa Biopharma (4114) has a cash flow conversion efficiency ratio of 0.018x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$185.72 Million ≈ $5.85 Million USD) by net assets (NT$10.10 Billion ≈ $318.18 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Synmosa Biopharma - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Synmosa Biopharma's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Synmosa Biopharma (4114) financial obligations for a breakdown of total debt and financial obligations.
Synmosa Biopharma Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Synmosa Biopharma ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Euroseas Ltd
NASDAQ:ESEA
|
0.083x |
|
Nanjing Aolian Ae&Ea Co Ltd
SHE:300585
|
0.024x |
|
HaiXin Foods Co Ltd
SHE:002702
|
0.122x |
|
Vastned Retail Belgium
BR:VASTB
|
0.015x |
|
Juniper Hotels Ltd
NSE:JUNIPER
|
0.023x |
|
Beijing Hanyi Innovation Technology Co. Ltd. A
SHE:301270
|
N/A |
|
Taiwan Shin Kong Security Co Ltd
TW:9925
|
0.044x |
|
Hangzhou Kaierda Welding Robot Co Ltd
SHG:688255
|
0.026x |
Annual Cash Flow Conversion Efficiency for Synmosa Biopharma (2015–2025)
The table below shows the annual cash flow conversion efficiency of Synmosa Biopharma from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see Synmosa Biopharma (4114) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$10.10 Billion ≈ $318.18 Million |
NT$411.57 Million ≈ $12.97 Million |
0.041x | -56.15% |
| 2024-12-31 | NT$8.40 Billion ≈ $264.61 Million |
NT$780.62 Million ≈ $24.59 Million |
0.093x | +47.08% |
| 2023-12-31 | NT$8.10 Billion ≈ $255.22 Million |
NT$511.93 Million ≈ $16.13 Million |
0.063x | -33.33% |
| 2022-12-31 | NT$6.65 Billion ≈ $209.47 Million |
NT$630.25 Million ≈ $19.86 Million |
0.095x | +30.05% |
| 2021-12-31 | NT$6.10 Billion ≈ $192.04 Million |
NT$444.29 Million ≈ $14.00 Million |
0.073x | +70.61% |
| 2020-12-31 | NT$5.95 Billion ≈ $187.60 Million |
NT$254.40 Million ≈ $8.02 Million |
0.043x | +558.15% |
| 2019-12-31 | NT$4.81 Billion ≈ $151.63 Million |
NT$-44.88 Million ≈ $-1.41 Million |
-0.009x | -361.48% |
| 2018-12-31 | NT$4.49 Billion ≈ $141.31 Million |
NT$16.00 Million ≈ $503.96K |
0.004x | +372.28% |
| 2017-12-31 | NT$3.97 Billion ≈ $124.93 Million |
NT$-5.19 Million ≈ $-163.64K |
-0.001x | -102.41% |
| 2016-12-31 | NT$4.35 Billion ≈ $137.14 Million |
NT$236.48 Million ≈ $7.45 Million |
0.054x | +593.84% |
| 2015-12-31 | NT$3.01 Billion ≈ $94.96 Million |
NT$23.60 Million ≈ $743.59K |
0.008x | -- |
About Synmosa Biopharma
Synmosa Biopharma Corporation, a specialty pharmaceutical company, researches, develops, manufactures, markets, and distributes pharmaceutical and healthcare products under the Synmosa brand in Taiwan. The company offers its products in various therapeutic areas, including cardiovascular, respiratory, urology, sex hormone, and oncology. The company also provides its products in various forms, suc… Read more